Early pregnancy failure is a major health problem throughout the world. According to an estimate, approximately 15% of all pregnancy ends to a spontaneous miscarriage, which means approximately 46 millions occur annually. 1 Many of these are performed illegally in unsafe situations resulting in approximately 47000 deaths worldwide in 2008. Complications from unsafe abortion accounted for an estimated 13% of all maternal death worldwide. 1 Expulsion of some but not all products of conception before 20 weeks of pregnancy abortion is incomplete abortion. 2 Evacuation of the uterus in incomplete abortion in which uterine size is < 12 weeks is usually performed by manual vacuum aspiration (MVA). However, it requires specialized equipment and skill with some risks of complications like cervical trauma, uterine perforation, infections etc.
INTRODUCTION
Lately, Misoprostol, a prostaglandin E1 analog, is being used which is a safe, effective and acceptable method to achieve uterine evacuation in incomplete abortion due to its uterotonic properties. [3] [4] [5] Misoprostol is cheap and can be used by different routes viz. per oral, sublingual, buccal, vaginal, and rectal. Similarly, different doses and regimens have been tried in different studies. 6 With the availability of this non-invasive management option, women are more inclined to accept this procedure. Furthermore, it doesn't require the surgical skills required to perform MVA. This study aims to find out about the safety, efficacy, and acceptability of misoprostol in comparison to MVA for the treatment of incomplete abortion.
MATERIALS AND METHODS
This was a prospective comparative interventional study, conducted at Paropakar Maternity and Women's Hospital, from October 2011 to March 2012. The study was conducted after approval from the hospital ethical committee. All patients fulfilling inclusion criteria were explained about the study, nature of the drug, it's side effects, possible limitations, and complications. The patients were included in the study after written consent was obtained. All women with clinical or ultrasound diagnosis incomplete abortion with less than 13 weeks of gestation according to the last menstrual period were included in the study. Patients with a uterine scar, septic/induced abortion, excessive bleeding, hemodynamically unstable, hemoglobin < 8 gm%, patient with active liver injury, lung and heart disease and patient known to allergy to E1 prostaglandin were excluded from the study. All the patients were divided into two groups: Group 1 included all odd numbers of cases under study group to whom Misoprostol 600 mcg was given orally. Group 2 included all even the number of cases under study group to whom MVA was done as standard treatment.
Women allocated to Group 1 were given Misoprostol 600 mcg orally. Women allocated to Group 2 were transferred to MVA room where trained staff did MVA. All women were given prophylactic antibiotics and Ibuprofen was prescribed for pain management if required. Both groups were observed for 4-6 hours and then discharged (except in case of continued and heavy per vaginal bleeding). They were also instructed to call the researcher if vaginal bleeding exceeded two soaked sanitary napkins in one hour for two consecutive hours. All women were asked to follow up after 7 days of treatment and each women's abortion status were assessed via clinical examination, including an interview and bimanual examination. Women with a substantial retained product of conception in the uterus on study day 7 were given the option of waiting an additional week for the uterus to evacuate on its own. Those unwilling to wait underwent MVA. If bleeding persisted after 2 weeks after examination pelvic ultrasound was performed and MVA was done in case of presence of the retained product of conception. During follow up the success of the procedure, the amount of blood loss, side effects of drugs, satisfaction, acceptability were enquired. Success was defined as complete uterine evacuation without the need for MVA in the medical management group and without the need for repeat vacuum aspiration in the surgical management group. Pain level was measured using a visual analog scale in which circles ranging in size from small ( no pain) to large (intense pain ) were used. The intraoperative blood loss was measured as the volume of the uterine aspirate after sieving away the POC in the MVA group. The amount of blood loss in the Misoprostol group was estimated on the basis of the number of pads soaked assuming that one sanitary pad soaked 50 ml blood. Bleeding during the period from the initial period up to follow up visit was noted as an adverse effect and was categorized as heavy bleeding (> menses, normal bleeding (= menses), light bleeding (< menses). To assess woman's satisfaction and acceptability, each participant was asked to mention the best and worst feature of her treatment and to indicate whether she would select the treatment again and recommend it to friends or not.
Statistical data analysis was done using SPSS (statistical package for social sciences). Statistical tests carried out for testing the significance were the Chi-square test and Student t-test. Values of P<0.05 were taken to indicate significance.
RESULTS
Among 1014 Gynecological admissions during the study period, 180 cases were of incomplete abortion. Out of them, 60 cases of incomplete abortion were enrolled in this study. 30 women were randomized into the Misoprostol group and 30 women were randomized into the MVA group. On most background characteristics the two groups didn't differ. (Table 1) Most of the patients were between 15 -34 year age group. Most of the patients had more than 1 parity (n=45; 75.0%). The success rate in the two groups was very high (misoprostol-93.33%; MVA-100%) and not statistically significant (p>0.05). Two patients (6.66%) in Group 1 had confirmed incomplete evacuation of the uterus by clinical examination on follow up and were subjected to MVA.
At follow up women in the misoprostol group experienced a significantly higher rate of adverse effects than MVA group (Table 2) . Diarrhoea, vomiting and fever were some of the more common incidences among the group 1 patient. In group 2, there were significantly low adverse effects. The common complaints were high pain score (n=24; 80%) followed by headache (n=7; 23.3%). In spite of the adverse effects of both procedures, women of the Misoprostol group were more satisfied than the MVA group (Table 3) . 
DISCUSSION
In the current study, the complete uterine evacuation rate was similar in both groups with a slight higher success rate in the MVA group. A similar finding was reported by Shwekerela et al in a study from Tanzania 7 and Montesionus et al. 8 In contrast to this finding, a study by Week's et al in Uganda showed Misoprostol to be more effective than MVA (96% vs. 92%). 9 While in other studies by Bano et al and Bique et al the success rate of MVA was 100% effective while Misoprostol was 92% and 91% effective. 10, 11 Similarly, in a study done by Ibiyemi KF et al, the success rate of MVA versus Misoprostol was 99% and 83% respectively. 12 The high success in our study is likely due to limited use of ultrasound and larger duration of follow up 14 days as shown by Tang et al. 13 Regarding the safety of both treatment modalities, the present study demonstrated that women's in the misoprostol group experienced more side effects than women in the MVA group. In Misoprostol group fever was a common and statistically significant side effect as compared to MVA group. A similar finding was observed by other studies. 7, 911, 14 The reason behind it is due to the main action of Misoprostol in central thermoregulatory centre. 15 Another common side effect was per vaginal bleeding in the Misoprostol group which is similar to a study conducted by Montensionus et al 8 where the bleeding was encountered in 22.6% patients in the misoprostol group in compared to only 6.7% in MVA group. MVA was identified as more painful than misoprostol (24; 80%), which is in agreement with a study done by Shwekerela et al. 7 and Bique et al 11 but in contrast to Niinimaki et al. 16 Diarrhea was found significantly high in Misoprostol than MVA group which was a similar finding in a study done by Pang et al. 17 In contrast, Phuong et al showed a low incidence of diarrhea in a single-dose regimen of misoprostol. 18 Misoprostol group showed significantly high cases of vomiting than the MVA group, which is similar to a study carried by Tang et al. 13 , In contrast, there was a low incidence of vomiting in a study conducted by Pang et al. 17 It is hypothesized that the high peak plasma concentration of misoprostol was cause of increased systemic side effects. 19 In spite of the adverse effects of both procedures, these side effects are transient and tolerable. As in other studies, the current participants include high satisfaction with both the misoprostol and the MVA group. 7, 8, 20 This finding was contrary to a study by Shwekerale et al where misoprostol had a significantly higher percentage of participant satisfaction than the MVA group (75% versus 55%) (P=0.001). 7 A comparatively high percentage of participants from both groups, in this study, expressed a desire to recommend their treatment method, which is in line with the findings of Dao et al. 19 In contrast, Shwekerale et al's study determined that a significantly higher proportion of participant in the Misoprostol group would recommend the treatment to friend than in MVA group ( 95 vs 75 %; p < 0.001). 7 The high satisfaction in both the procedures is due to availability with ease, shorter hospital stay, fewer complications.
In a poor country like ours where surgical evacuation facilities are limited, lack of skilled surgical providers and equipment, the use of 600 mcg Misoprostol orally, by health providers, can be life-saving and help us in reducing maternal mortality. Although Misoprostol is a very effective drug, the health care professional should have thorough knowledge of the dose, side effects, complications and contraindications before prescribing it.
CONCLUSIONS
The efficacy of oral Misoprostoiis is as effective as MVA in the treatment of first trimester incomplete abortion with comparable success rate. Though Misoprostol had more side effects it's satisfaction and acceptability were comparable with the MVA group.
